SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Eiko Lifesciences informs about press release

09 Feb 2022 Evaluate
Eiko Lifesciences has informed that it enclosed the E-newspaper copies of the unaudited Financial Results of the Company for the 3rd quarter and Nine month ended 31st December 2021 published in The Financial Express (in English), and Mumbai Lakshadweep (In Marathi), on Wednesday, February 09, 2022. 

The above information is a part of company’s filings submitted to BSE.

Eiko Lifesciences Share Price

50.46 0.25 (0.50%)
30-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
BASF India 3640.10
Tata Chemicals 809.45
SRF 2519.20
Pidilite Inds. 1375.55
Deepak Nitrite 1736.90
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×